Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 17/20 | 1.00 |
| ▸ | MTOR | P42345 | 16/20 | 1.00 |
| ▸ | ATR | Q13535 | 7/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17246146 | 1.00 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL29355614 | 1.00 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17242588 | 0.95 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17246304 | 0.95 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17246341 | 0.95 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL19456280 | 0.94 | ATM (0.88) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17272541 | 0.93 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL20006457 | 0.93 | ATM (0.97) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL22675397 | 0.92 | ATM (0.85) | ATMPIK3CAMTORATRPIK3CD | |
| SCHEMBL17241421 | 0.92 | ATM (1.00) | ATMPIK3CAMTORATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683909-A2 | ATM KINASE INHIBITORS | Eberhard Karls Universität Tübingen (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20260015328-A1 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2026-01-15 | — | — | US | disclosed |
| WO-2025109076-A1 | BIOMARKERS FOR IDENTIFYING PATIENTS HAVING TUMORS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY | INSTITUT CURIE (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025088175-A1 | ALC1 INHIBITORS FOR USE IN TREATING CANCER BY POTENTIATING THE EFFECTS OF SEVERAL CLASSES OF APPROVED CANCER DRUGS | EISBACH BIO GMBH (DE) | 2025-05-01 | — | — | WO | disclosed |
| US-20240408077-A1 | ATM KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL CONDITIONS | THE UNIVERSITY OF BIRMINGHAM (GB) | 2024-12-12 | — | — | US | disclosed |
| WO-2024194460-A2 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2024-09-26 | — | — | WO | disclosed |
| EP-4434972-A1 | ATM KINASE INHIBITORS | Eberhard-Karls-Universität Tübingen (DE) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023062375-A1 | ATM KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL CONDITIONS | THE UNIVERSITY OF BIRMINGHAM (GB) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408077-A1 | ATM KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL CONDITIONS | ATM, CHEK2, ATR | ATM 1/4885PIK3CA 871/4885MTOR 113/4885 |
| US-20260015328-A1 | ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | ATM 1/4885PIK3CA 326/4885MTOR 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.